RAPID IMPROVEMENT IN BIPOLAR II DEPRESSION INDUCED BY LOW-DOSE LAMOTRIGINE AUGMENTATION: TWO CASE REPORTS

To the Editor:

The role of antidepressants in the treatment of the depressed phase of bipolar disorder remains controversial due to risk of induction of hypomania, mixed episodes, and rapid cycling.1,2 In addition, antidepressants may not be as efficacious in the management of the depressed phase of bipolar disorder as they are in the management of major depressive disorder. Many experts believe that the treatment of bipolar depression should include antidepressants in combination with an antimanic drug such as lithium.3 However, few studies are available that guide the next best treatment if a mood stabilizer plus an antidepressant fails to help patients with bipolar depression. The limited available data suggests that patients can be switched to either electroconvulsive therapy or monoamine oxidase inhibitors (MAOs).4,5 Other options include combining mood stabilizers,6 switching to the combination of olanzapine and fluoxetine,7 and switching to quetiapine.8

Recently, lamotrigine has been found to be efficacious in the long-term management of bipolar disorder (especially in delaying depressive recurrence), either as a monotherapy or adjunctive therapy, but its efficacy in the acute treatment of bipolar depression is less clear.9,10

However, to our knowledge, there is no literature available that addresses rapid improvement induced by low-dose lamotrigine augmentation in bipolar II depression. Here, we report two cases of bipolar II depressed patients who did not respond to two different antidepressant trials that lasted for >8 weeks, but subsequently showed rapid improvement after low-dose lamotrigine augmentation.

Case 1

Mrs. M was a 45-year-old married woman with a primary school education who was admitted to our hospital. She had suffered from bipolar II disorder for the previous 5 years and had experienced three depressive episodes and one hypomanic episode within that time. The first episode of her illness was a depressive episode at 34 years of age. She had been treated with various atypical antipsychotics, mood stabilizers including lithium, and various antidepressants including paroxetine, escitalopram, and sertraline during this period.

Upon examination, she was found to suffer from severe pervasive sadness; anhedonia; hypersomnia; severe psychomotor retardation; feelings of worthlessness; distractibility; occasional passive suicidal ideation; and decreased energy, concentration, appetite, and self-esteem. She remained in bed most of the time, rarely cared for herself, and could not work. She experienced these symptoms on most days and nearly every day during the month prior to admission. This was the fourth depressive episode of her illness. Her 17-item Hamilton Depression Rating Scale (HAMD-17) score was 31. An 8-week trial of escitalopram failed to consistently improve her depression. Subsequently, her medication was replaced by venlafaxine, which has a more rapid onset of action and is often used in bipolar depression. Venlafaxine was started at a dose of 75 mg/day and gradually increased to 300 mg/day within 2 weeks. At week 6 of venlafaxine treatment, there was no significant improvement in her depressive symptoms. Her HAMD total score was 26. Therefore, lithium was added to her medication and gradually increased to 900 mg/day (the mean plasma levels were 0.77). Since the clinical response at week 4 after lithium augmentation was only partial, 25 mg/day lamotrigine was added to this regimen. The patient responded to lamotrigine after 3 days of treatment while on a dose of 25 mg/day. The patient reported increased energy, improvement in hypersomnia, a greater ability to concentrate, and increased appetite.

After 1 week of treatment, there was a significant clinical improvement in her depression. Her HAMD total score was 8. The individual symptoms that showed rapid improvements (week 1) were depressed mood (HAMD item 1), feelings of guilt (HAMD item 2), suicide (HAMD item 3), work and activities (HAMD item 7), and anxiety psychic (HAMD item 10). On day 9 of combination therapy, her depressive symptoms remitted completely with no evidence of adverse effects. The final HAMD total score was 2. In addition, there were no symptoms suggestive of either a mixed episode or hypomanic state. The patient continued this combination regimen, including lamotrigine 300 mg/day, lithium 900 mg/day, and quetiapine 25 mg/day, without recurrence of depression or emergence of hypomania or adverse effects for 2 months.

Case 2

Mrs. G was a 41-year-old married woman with a high school education who was admitted to our inpatient clinic. She had suffered from bipolar II disorder for the previous 7 years and had experienced six depressive episodes and two hypomanic episodes within that time. The first episode of her illness was a depressive episode at 34 years of age. She had been treated with various antipsychotics (including quetiapine, olanzapine, and risperdone), mood stabilizers (including lithium), and antidepressants (including sertraline, venlafaxine, and escitalopram) during this period. She had been regularly maintained on a treatment regimen (including lithium 1,200 mg/day and quetiapine 200 mg/day) for 2 months when she experienced a depressive episode. The mean plasma level of lithium was 0.82. Upon examination, she was found to suffer from severe pervasive sadness, anhedonia, insomnia, moderate psychomotor retardation, feelings of worthlessness, distractibility, recurrent suicidal ideation, somatic symptoms, and somatic anxiety as well as decreased energy, concentration, and appetite. Her HAMD total score was 34. In light of this, escitalopram was added to the ongoing lithium and quetiapine treatment. An 8-week escitalopram trial failed to consistently improve her depression. Subsequently, her medication was replaced with sertraline. Sertraline was started at a dose of 50 mg/day and gradually increased to 150 mg/day. After 8 weeks of sertraline treatment, there was no significant improvement in her depressive symptoms. Her HAMD total score was 28. Subsequently, 25 mg/day lamotrigine was added to her treatment regimen. The patient responded to lamotrigine after ~2 days of treatment while on a dose of 25 mg/day. The patient experienced a significant improvement in HAMD scores for suicide, insomnia, retardation, general somatic symptoms, and anxiety somatic. Within 1 week, the patient’s HAMD total score dramatically decreased from 28 to 9. In addition, there were no symptoms suggestive of either a mixed episode or hypomanic state. The patient continued this combination regimen, including sertraline 150 mg/day, lamotrigine 25 mg/day, lithium 1,200 mg/day, and quetiapine 200 mg/day, without recurrence of depression or emergence of hypomania or adverse effects for 2 months.

Discussion

Previous studies have suggested that lamotrigine, used alone or in combination with other psychotropic drugs, is safe and effective in the management of bipolar II depression, but not mania.11,12,13 However, for the acute treatment of bipolar II depression, lithium, lamotrigine, and quetiapine have been recommended as second-line options and there is insufficient information to recommend any medication as a first-line treatment.11,14

The exact mechanism by which lamotrigine exerts its action has not been completely elucidated, but a number of putative neurochemical effects have been postulated. In forced swim test, increased swimming and decreased immobility indicate antidepressant-like effect. It has been demonstrated that, when combined with veratrine, a Na-
channel opener, the antidepressant-like effect of lamotrigine is reversed, but that the antidepressant-like effect of imipramine, desipramine, and paroxetine is not changed. This finding indicates that the mechanism of action of lamotrigine is different from that of antidepressants.\(^{11}\) It has been suggested that the antidepressant-like effect of lamotrigine is related to the noradrenergic system, likely due to an activation of \(\alpha_2\) and \(\alpha_3\)-postsynaptic adrenoceptors, and serotoninergic systems.\(^{16,17}\) Muck-Seler and colleagues\(^{18}\) found that lamotrigine has an effect on platelet MAO-B activity in patients with bipolar depression, and they suggested that its in vivo MAO-B inhibiting effect might have contributed, in part, to its antidepressant activity. On the other hand, there is evidence that bipolar depression is characterized by increased glutamate coupled with increased energy expenditure. Evidence has also suggested that in patients with refractory affective disorder, excitatory amino acids are dysregulated. Lamotrigine appears to reduce glutamine levels associated with treatment remission. This may be another action mechanism of lamotrigine in bipolar depression treatment.\(^{19}\)

In the present study, low-dose lamotrigine induced rapid improvement from depressive symptoms in bipolar II disorder; however, the mechanism behind this result is unclear. Its broader action mechanism (with effects on noradrenergic, dopaminergic, serotonergic, and glutamatergic neurotransmission, MAO-B inhibiting effect, and the effects of sodium and calcium channel) may be an explanation for the rapid and sustained improvement induced by its low-dose augmentation in the reported cases. The literature suggests that atypical antipsychotics may induce a rapid improvement in individuals with depression. For example, rapid improvement associated with the augmentation strategy has been described in relation to olanzapine and risperidone in previous studies.\(^{19}\) The findings in the current study suggest that atypical antipsychotics may increase the risk of switch to mania in patients with bipolar II depression. However, the mechanisms behind the rapid improvement induced by lamotrigine in the reported cases remains unclear. Controlled studies are necessary to understand the pharmacologic mechanisms underlying rapid improvement in bipolar II depression following treatment with low-dose lamotrigine.

Sincerely,
Omer Ali Ceyhan, MD
Okan Ekin, MD
Ali Caykoylu, MD

References
A SEVERE CASE OF BUPROPION HYDROCHLORIDE EXTENDED-RELEASE MONOTHERAPY-ASSOCIATED VISUAL HALLUCINATIONS AND DELIRIUM IN A FEMALE PATIENT WITH MAJOR DEPRESSIVE DISORDER

To the Editor:

Bupropion is thought to exert antidepressant effects via inhibition of dopamine and norepinephrine reuptake. Several recent reports have suggested that bupropion may promote the development of psychotic symptoms such as delusions and hallucinations in various patient populations. For example, bupropion treatment has been associated with delirium characterized by disorganized thinking, memory impairment, fear, and agitation without disorientation, delusions, hallucinations, or other perceptive distortions; psychotic episodes due to bupropion overdose;1–4 paranoid delusions and hallucination after combination with other agents;5–8 tactile hallucinations;9 and psychosis in patients receiving low-dose bupropion with comorbid psychiatric and/or medical disorders.12–15 Given the known relationship between enhanced dopaminergic function and psychotic symptoms,16 exacerbation or precipitation of psychotic symptoms by modulation of dopamine transmission is perhaps unsurprising. However, to our knowledge, there have been no reports of the combined development of visual hallucinations and a delirious episode associated with the slow titration of bupropion hydrochloride extended-release (bupropion XL) monotherapy. This case report describes a patient presenting with major depressive disorder who suffered from visual hallucinations and delirium after titration of bupropion XL from 150 mg/day to 300 mg/day.

Ms. A was a 28-year-old woman with no family history of psychiatric disorders, who presented with a major depressive episode that had persisted for ~2 months. She had no clinically significant comorbid medical or psychiatric conditions. Her depressive symptoms were moderate and without psychotic features, consisting primarily of depressed mood, lack of energy, loss of interest, tearfulness, decreased motivation, fatigue, loss of appetite, and hopelessness. She had no previous exposure to antidepressants. After the patient was briefed on the potential benefits and risks of bupropion, an initial 2-week course of bupropion XL 150 mg/day was prescribed, in addition to twice daily alprazolam 0.25 mg/day. At the time of her next visit, Ms. A’s depressive symptoms had responded a bit to the initial bupropion XL dose; specifically, she reported improvement in energy levels and concentration. She had no issues with tolerability, with the exception of mild sleep disturbance, and thus the dose of bupropion XL was increased to 300 mg/day. Four days after she began taking the increased dose of bupropion XL, she saw a group of ants crawling on a wall and became disoriented with associated psychomotor slowing. At this point she was brought to the emergency room by her boyfriend and mother. Neurological and neurosurgical consultation ruled out any potential organic causes. After admission, bupropion XL was immediately discontinued, and she was treated conservatively, without neuroleptics. Her condition began to improve shortly thereafter (hospital day 2); she had completely recovered by hospital day 5 without any residual symptoms, and was discharged.

The present case is the first to report the combined clinical manifestation of visual hallucinations and delirium associated with bupropion XL monotherapy after a dose increase from 150 mg/day to 300 mg/day.

Previous reports of transient psychotic symptoms due to bupropion predominantly involved cases of overdose,2–3 combination therapy,4,5–8 or high therapeutic doses,4,12–15 with patients frequently presenting with comorbid psychiatric and/or medical disorders. An interesting point is that the majority of these cases involved female patients, suggesting an increased vulnerability of the female gender to bupropion-induced psychotic symptoms. Although the exact mechanism underlying the development of psychosis remains unclear, the most likely possibilities include alterations in dopaminergic neurotransmission and effects arising from the structural similarities of bupropion and amphetamine. According to a previous report,19 risk factors for bupropion-associated psychosis include a history of psychotic episodes, comorbid medical disorders, combination of psychotropic drugs, concurrent use of a dopaminergic agent, and advanced age. Contributing factors to delirium may include increased dopaminergic activity, interaction with other medications, and accumulation of bupropion’s active metabolite, hydroxybupropion.21

Earlier studies are largely similar to our case report and suggest that clinicians need to carefully monitor symptomatic changes in patients after starting bupropion treatment. The most notable point in the present case is the simultaneous onset of visual hallucinations and delirium that began four days after increasing the dose of bupropion XL, and disappeared completely upon cessation of bupropion treatment. Hence, we cautiously suggest that bupropion XL may have a dose-dependent propensity for inducing acute psychotic symptoms, combination of psychotropic drugs, concurrent use of a dopaminergic agent, and advanced age. Contributing factors to delirium may include increased dopaminergic activity, interaction with other medications, and accumulation of bupropion’s active metabolite, hydroxybupropion.21

Please direct all correspondence to: Ankara Ataturk Education and Research Hospital in Ankara, Turkey.

Faculty Disclosures: Dr. Ozer, Ekinci, and Caykoylu report no financial or financial interest in any organization that may pose a conflict of interest.

Dr. Ozer is specialist of psychiatry, Dr. Ekinci is research assistant of psychiatry, and Dr. Caykoylu is professor and clinical director in the Department of Psychiatry at Ataturk Education and Research Hospital in Ankara, Turkey.

Dr. Ozer is specialist of psychiatry, Dr. Ekinci is research assistant of psychiatry, and Dr. Caykoylu is professor and clinical director in the Department of Psychiatry at Ataturk Education and Research Hospital in Ankara, Turkey.

Submitted for publication: January 21, 2009, Accepted for publication: August 5, 2009.

Please direct all correspondence to: Ankara Ataturk Education and Research Hospital, Ankara, Turkey. Tel: +90-312.2911252, Fax: +90-312.29121705; Email: dlokanekinci@yahoo.com.

References


© MBL Communications Inc. September 2010

https://doi.org/10.1017/S10902859200000584 Published online by Cambridge University Press
zodiaepines are also related to development of psychosis, delirium, and behavioral toxicity. Possible influences of specific genetic polymorphisms, particularly those relating to the pharmacokinetic and pharmacodynamic properties of bupropion XL or of the patient’s premorbid personality traits should be also considered. With respect to treating the patient’s depressive symptoms after the adverse reaction to bupropion XL, switching to a different class of drugs, such as selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, or nor- epinephrine and specific serotonin anti-depressants would probably be beneficial.

This case suggests that patients treated with bupropion XL should be carefully monitored, particularly when certain risk factors are present, and treatment should be tailored based on the potential vulnerability of the patient to psychosis.

Sincerely,

Chi-Un Pae, MD, PhD

References